Dihydroergotamine Nasal Spray During Migraine Attacks: A Double-Blind Crossover Study with Placebo
- 1 June 1987
- journal article
- research article
- Published by SAGE Publications in Cephalalgia
- Vol. 7 (2) , 131-133
- https://doi.org/10.1046/j.1468-2982.1987.0702131.x
Abstract
Ergot derivatives have been used in the treatment of migraine for more than 50 years. We have compared the efficacy of dihydroergotamine (DHE) nasal spray with that of placebo in patients with classic or common migraine attacks. The study was performed in accordance with a double-blind, crossover design. In this study a great placebo effect was observed with a dose of 1.36 mg/attack, and the overall efficacy was rated by the patients to be 41% and 52% for placebo and DHE, respectively.Keywords
This publication has 4 references indexed in Scilit:
- Dihydroergotamine Nasal Spray for the Treatment of Migraine Attacks: A Comparative Double-Blind Crossover Study with PlaceboCephalalgia, 1985
- A Double Blind Trial with Dihidroergotamine Spray in Migraine CrisisCephalalgia, 1985
- Dihydroergotamine Nasal Spray in the Treatment of Migraine AttacksCephalalgia, 1985
- Efficacy of Dihydroergotamine Nasal Spray in the Acute Treatment of Migraine AttacksCephalalgia, 1985